Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C W Hendrix

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Annals of Internal Medicine|October 1, 1989
Dextran sulfate is poorly absorbed after oral administrationK J Lorentsen, C W Hendrix, J M Collins, et al.
International Journal of STD & AIDS|September 2, 2018
Oral and vaginal HIV pre-exposure prophylaxis product attribute preferences among female sex workers in the Mexico-US border regionH A Pines, S A Strathdee, C W Hendrix, et al.
The Journal of Infectious Diseases|May 1, 1991
Comparison of spinal fluid beta 2-microglobulin levels with CD4+ T cell count, in vitro T helper cell function, and spinal fluid IgG parameters in 163 neurologically normal adults infected with the human immunodeficiency virus type 1D R Lucey, S A McGuire, M Clerici, et al.
The Journal of Infectious Diseases|September 1, 1989
Ceftriaxone compared with cefotaxime for serious bacterial infectionsC R Smith, B G Petty, C W Hendrix, et al.
The Journal of Infectious Diseases|October 1, 1991
Human immunodeficiency virus infection in the US Air Force: seroconversions, clinical staging, and assessment of a T helper cell functional assay to predict change in CD4+ T cell countsD R Lucey, G P Melcher, C W Hendrix, et al.
Journal of Clinical Microbiology|January 1, 1992
Comparison of antibody reactivity to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in sera from HIV-1-infected individuals from Tanzania and from the United StatesR Q Warren, W M Nkya, J F Shao, et al.
The Journal of Infectious Diseases|December 1, 1993
Longitudinal analysis of the humoral immune response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and nonprogressing HIV-1-infected subjectsM T Wong, R Q Warren, S A Anderson, et al.
Annals of Internal Medicine|August 1, 1993
Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV-infected patientsS P Blatt, C W Hendrix, C A Butzin, et al.
Antimicrobial Agents and Chemotherapy|June 11, 2014
Safety and pharmacokinetics of XOMA 3AB, a novel mixture of three monoclonal antibodies against botulinum toxin AS U Nayak, J M Griffiss, R McKenzie, et al.
The Journal of Infectious Diseases|July 1, 1995
In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virusM J Dolan, M Clerici, S P Blatt, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Annals of Internal Medicine|October 1, 1989
Dextran sulfate is poorly absorbed after oral administrationK J Lorentsen, C W Hendrix, J M Collins, et al.
International Journal of STD & AIDS|September 2, 2018
Oral and vaginal HIV pre-exposure prophylaxis product attribute preferences among female sex workers in the Mexico-US border regionH A Pines, S A Strathdee, C W Hendrix, et al.
The Journal of Infectious Diseases|May 1, 1991
Comparison of spinal fluid beta 2-microglobulin levels with CD4+ T cell count, in vitro T helper cell function, and spinal fluid IgG parameters in 163 neurologically normal adults infected with the human immunodeficiency virus type 1D R Lucey, S A McGuire, M Clerici, et al.
The Journal of Infectious Diseases|September 1, 1989
Ceftriaxone compared with cefotaxime for serious bacterial infectionsC R Smith, B G Petty, C W Hendrix, et al.
The Journal of Infectious Diseases|October 1, 1991
Human immunodeficiency virus infection in the US Air Force: seroconversions, clinical staging, and assessment of a T helper cell functional assay to predict change in CD4+ T cell countsD R Lucey, G P Melcher, C W Hendrix, et al.
Journal of Clinical Microbiology|January 1, 1992
Comparison of antibody reactivity to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in sera from HIV-1-infected individuals from Tanzania and from the United StatesR Q Warren, W M Nkya, J F Shao, et al.
The Journal of Infectious Diseases|December 1, 1993
Longitudinal analysis of the humoral immune response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and nonprogressing HIV-1-infected subjectsM T Wong, R Q Warren, S A Anderson, et al.
Annals of Internal Medicine|August 1, 1993
Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV-infected patientsS P Blatt, C W Hendrix, C A Butzin, et al.
Antimicrobial Agents and Chemotherapy|June 11, 2014
Safety and pharmacokinetics of XOMA 3AB, a novel mixture of three monoclonal antibodies against botulinum toxin AS U Nayak, J M Griffiss, R McKenzie, et al.
The Journal of Infectious Diseases|July 1, 1995
In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virusM J Dolan, M Clerici, S P Blatt, et al.
Pageof 6